VJHemOnc is committed to improving our service to you

ASCO 2019 | Second generation BTK-inhibitors for CLL

VJHemOnc is committed to improving our service to you

Susan O’Brien

BTK-inhibitors present a good option for many CLL patients. Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses the use of BTK-inhibitors for chronic lymphocytic leukemia and which she believes are most clinically relevant. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter